Shots:

• Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies- in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD
• The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience  
•  Yumanity and Merck will collaborate to advance the two preclinical programs during the research term- after which Merck will lead the clinical development and commercialization  

Click here to read full press release/ article 

Ref: Merck | Image: Merck